Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00804596 · ClinicalTrials.gov registry record · NA

Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System

A NA study of Diabetes, sponsored by Ascensia Diabetes Care.

Completed
Registry status
NA
Development phase
74
Enrollment target
1
Study location

NCT00804596 is a NA study of Diabetes that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 74 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00804596, a NA study of Diabetes, has completed, sponsored by Ascensia Diabetes Care.

COMPLETED
Registry status
NA
Development phase
74 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study was to evaluate the acceptability of product user guides for untrained subjects and to evaluate the performance of the system with lay users and healthcare providers (HCPs).

Conditions Studied

Interventions

  • DEVICE Apollo Blood Glucose Monitoring System

Study Locations (1)

Minnesota

  • International Diabetes Center - Minneapolis

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2008-12
Est. Completion 2009-01
Phase NA

Sponsor

Ascensia Diabetes Care

42 total trials

What the Registry Record Tells You About NCT00804596

The ClinicalTrials.gov registry entry for NCT00804596 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Ascensia Diabetes Care, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Apollo Blood Glucose Monitoring System is the first listed.

NCT00804596 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00804596 about?

NCT00804596 is a clinical study titled "Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System". The purpose of the study was to evaluate the acceptability of product user guides for untrained subjects and to evaluate the performance of the system with lay users and healthcare providers (HCPs).

What is the current status of trial NCT00804596?

This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2008-12. Estimated completion is 2009-01.

What conditions does trial NCT00804596 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT00804596?

The interventions under investigation include: Apollo Blood Glucose Monitoring System (DEVICE).

Who is sponsoring clinical trial NCT00804596?

This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00804596 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.